Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus TOLECTIN DS.
EC-NAPROSYN vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
500-1000 mg orally twice daily; maximum 1500 mg/day.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category C
Category C
NSAID
NSAID